Phase II Study of High-Dose Rituximab in High-Risk Chronic Lymphocytic Leukemia Patients in Suboptimal Response After Induction Immunochemotherapy
Phase of Trial: Phase II
Latest Information Update: 02 Oct 2015
At a glance
- Drugs Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms HYDRIC
- 28 Sep 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 11 Aug 2014 Status changed from not yet recruiting to recruiting, as per European Clinical Trials Database record.
- 27 Jun 2012 New trial record